TWI906350B - 包括氯胺酮的微球調配物、其製造方法及使用於方法中之組合物 - Google Patents

包括氯胺酮的微球調配物、其製造方法及使用於方法中之組合物

Info

Publication number
TWI906350B
TWI906350B TW110130523A TW110130523A TWI906350B TW I906350 B TWI906350 B TW I906350B TW 110130523 A TW110130523 A TW 110130523A TW 110130523 A TW110130523 A TW 110130523A TW I906350 B TWI906350 B TW I906350B
Authority
TW
Taiwan
Prior art keywords
ketamine
polymer
microspheres
homogenizer
microsphere
Prior art date
Application number
TW110130523A
Other languages
English (en)
Chinese (zh)
Other versions
TW202227044A (zh
Inventor
瑞秋 加拉斯卡
凱爾西 卡特
崔西 里奇
Original Assignee
美商奧克伍德實驗有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商奧克伍德實驗有限公司 filed Critical 美商奧克伍德實驗有限公司
Publication of TW202227044A publication Critical patent/TW202227044A/zh
Application granted granted Critical
Publication of TWI906350B publication Critical patent/TWI906350B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
TW110130523A 2020-08-18 2021-08-18 包括氯胺酮的微球調配物、其製造方法及使用於方法中之組合物 TWI906350B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063067068P 2020-08-18 2020-08-18
US63/067,068 2020-08-18
US202163149911P 2021-02-16 2021-02-16
US63/149,911 2021-02-16

Publications (2)

Publication Number Publication Date
TW202227044A TW202227044A (zh) 2022-07-16
TWI906350B true TWI906350B (zh) 2025-12-01

Family

ID=80270269

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110130523A TWI906350B (zh) 2020-08-18 2021-08-18 包括氯胺酮的微球調配物、其製造方法及使用於方法中之組合物

Country Status (10)

Country Link
US (1) US12233165B2 (https=)
EP (1) EP4199917B1 (https=)
JP (1) JP7814375B2 (https=)
KR (1) KR20230052915A (https=)
CN (1) CN115942935B (https=)
AU (1) AU2021329820A1 (https=)
CA (1) CA3191160A1 (https=)
IL (1) IL300547A (https=)
TW (1) TWI906350B (https=)
WO (1) WO2022040130A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2907692T3 (es) 2017-12-29 2022-04-26 Celon Pharma Sa Composición de ketamina de polvo seco para su administración por vía pulmonar en la depresión resistente al tratamiento
EP4611729A1 (en) * 2022-10-31 2025-09-10 Oakwood Laboratories, LLC Mixed release profile polymer microsphere formulations comprising octreotide and methods for making and using the same

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0720859B2 (ja) * 1985-02-07 1995-03-08 武田薬品工業株式会社 マイクロカプセルの製造法
US6902743B1 (en) * 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
US5945126A (en) 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
US6291013B1 (en) * 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
AU6510400A (en) 1999-08-04 2001-03-05 Oakwood Laboratories L.L.C. Slow release microspheres
US6479007B1 (en) 1999-09-16 2002-11-12 University Technology Corporation Apparatus and method for controlling pore size in polymeric membranes and thin films
KR100392501B1 (ko) 2000-06-28 2003-07-22 동국제약 주식회사 다중 에멀젼법에 의한 서방출성 미립구의 제조방법
EP1387671A1 (en) * 2001-05-03 2004-02-11 MASSACHUSETTS EYE & EAR INFIRMARY Implantable drug delivery device and use thereof
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
WO2005107714A2 (en) 2004-05-05 2005-11-17 Alkermes Controlled Therapeutics, Inc. Method of forming microparticles that include a bisphosphonate and a polymer
KR101271263B1 (ko) 2005-09-28 2013-06-07 아우리스 메디칼 아게 내이 장애 치료용 약학 조성물
CA2635374C (en) 2006-01-11 2015-12-08 Hyperbranch Medical Technology, Inc. Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices
US20070292521A1 (en) * 2006-06-20 2007-12-20 Schwitzer Co., Ltd Oral Encapsulated Preparation for Aquatic Animals
US20110027331A1 (en) 2009-07-29 2011-02-03 Warsaw Orthopedic, Inc. An implantable drug depot having a reversible phase transition material for treatment of pain and/or inflammation
WO2013119183A1 (en) 2012-02-06 2013-08-15 Nanyang Technological University Methods of manufacturing core-shell microparticles, and microparticles formed thereof
WO2013138322A1 (en) * 2012-03-12 2013-09-19 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
WO2017075136A1 (en) 2015-10-27 2017-05-04 Purdue Research Foundation Polymer-based therapeutics for inductive browning of fat
SG11202001206YA (en) 2017-09-14 2020-03-30 Agency Science Tech & Res Emulsions, methods and uses thereof
KR20240011237A (ko) 2017-12-22 2024-01-25 얀센 파마슈티카 엔브이 우울증 치료를 위한 에스케타민
EP3968979A4 (en) 2019-05-15 2023-03-01 Bexson Biomedical, Inc. KETAMINE FORMULATION FOR SUBCUTANEOUS INJECTION
EP3993898B1 (en) 2019-07-01 2025-10-15 Oakwood Laboratories, Llc System and method for making microspheres and emulsions
US20220401366A1 (en) * 2019-11-15 2022-12-22 Consegna Pharma, Inc. Long acting nmda antagonists
PH12022550775A1 (en) 2019-12-20 2023-08-23 Alar Pharmaceuticals Inc Long-acting injectable formulations of ketamine pamoate salts
US20210361578A1 (en) 2020-04-03 2021-11-25 University Of Iowa Research Foundation Mek1/2 inhibitor-loaded microparticle formulation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 FELICITY Y. HAN Novel Polymeric Bioerodable Microparticles for Prolonged-Release Intrathecal Delivery of Analgesic Agents for Relief of Intractable Cancer-Related Pain J Pharm Sci. 104 2015 Jul 2334-2344

Also Published As

Publication number Publication date
TW202227044A (zh) 2022-07-16
CA3191160A1 (en) 2022-02-24
EP4199917C0 (en) 2026-01-07
EP4199917A4 (en) 2024-10-30
US12233165B2 (en) 2025-02-25
EP4199917B1 (en) 2026-01-07
WO2022040130A1 (en) 2022-02-24
US20220054420A1 (en) 2022-02-24
CN115942935A (zh) 2023-04-07
JP2023538901A (ja) 2023-09-12
EP4199917A1 (en) 2023-06-28
IL300547A (en) 2023-04-01
JP7814375B2 (ja) 2026-02-16
AU2021329820A1 (en) 2023-03-09
CN115942935B (zh) 2025-09-05
KR20230052915A (ko) 2023-04-20

Similar Documents

Publication Publication Date Title
JP2016513721A (ja) 高薬物含有ブプレノルフィンマイクロスフェア及びその製造方法
EP3946272B1 (en) Method for preparing biocompatible polymer-based apixaban-loaded microspheres
KR102045721B1 (ko) 아픽사반 함유 미립구 제조용 분산상의 조성물 및 이로부터 제조되는 생체적합성 고분자 기반 아픽사반 함유 미립구
TWI906350B (zh) 包括氯胺酮的微球調配物、其製造方法及使用於方法中之組合物
CN103893129B (zh) 帕潘立酮缓释微球及其注射剂和该缓释微球的制备方法
WO2022198167A1 (en) Microsphere formulations comprising naltrexone and methods for making and using the same
US11992559B2 (en) Microsphere formulations comprising lurasidone and methods for making and using the same
US20240342115A1 (en) Microsphere formulations comprising ketamine and methods formaking and using the same
ES3061392T3 (en) Microsphere formulations comprising ketamine and methods for making and using the same
US20230225993A1 (en) Microsphere formulations comprising ketamine and methods for making and using the same
WO2023133554A2 (en) Microsphere formulations comprising ketamine and methods for making and using the same
US20240000772A1 (en) Microsphere formulations comprising naltrexone and methods for making and using the same
KR20230154222A (ko) Btk 억제제를 포함하는 마이크로스피어 제제 및 이의 제조 및 사용 방법
US20240307381A1 (en) Microsphere formulations comprising lurasidone and methods for making and using the same
US20230404922A1 (en) Microsphere formulations comprising btk inhibitors and methods for making and using the same
JP2026507990A (ja) オクトレオチドを含む混合放出プロファイルポリマーミクロスフェア製剤ならびにその製造方法及び使用方法
WO2025117624A1 (en) Microsphere formulations comprising brexpiprazole and methods for making and using the same
WO2024163997A1 (en) Microsphere formulations comprising naltrexone and methods for making and using the same
WO2023097204A1 (en) Microsphere formulations comprising asenapine and methods for making and using the same